[Form 4] Disc Medicine, Inc. Insider Trading Activity

Rhea-AI Filing Summary

John D. Quisel, who serves as Chief Executive Officer and a director of Disc Medicine, Inc. (IRON), reported two related transactions dated 09/09/2025. He acquired 10,000 shares of common stock at $1.01 per share, bringing his total direct common stock holdings to 171,828 shares. On the same date he was granted or reported a stock option to buy 10,000 shares with an exercise price of $1.01, exercisable immediately and expiring 03/10/2030, increasing his total beneficial ownership including derivatives to 198,420 shares. The filing states the optioned shares are fully vested and exercisable as of the report date.

Positive

• CEO and director increased direct ownership to 171,828 shares via a 10,000-share acquisition at $1.01
• Total beneficial ownership rose to 198,420 shares after adding a fully vested 10,000-share option exercisable immediately
• Options are fully vested and exercisable, aligning executive incentives with shareholders through 03/10/2030

Negative

• None.

Insights

Securities Analyst

TL;DR Insider purchased shares and holds fully vested options, modestly increasing direct and total beneficial ownership.

The Form 4 discloses a direct purchase of 10,000 common shares at $1.01 and a concurrently reported option for 10,000 shares at the same $1.01 exercise price. The reporting person is CEO and director, and the option is fully vested and exercisable through 03/10/2030. For investors, insider purchases by senior executives can signal confidence in company prospects; the recorded transactions materially raise his direct stake to 171,828 shares and total beneficial ownership to 198,420 shares.

Corporate Governance Expert

TL;DR CEO/director transaction shows alignment of executive incentives via vested options and an additional open-market or grant purchase.

The filing documents both a non-derivative acquisition and a derivative position that is fully vested. From a governance standpoint, the combination of direct share acquisition and vested options increases the CEO's exposure to shareholder outcomes. The filing is routine in form and includes signature by an attorney-in-fact, complying with Section 16 reporting requirements.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Quisel John D

(Last) (First) (Middle)

C/O DISC MEDICINE, INC.

321 ARSENAL STREET, SUITE 101

(Street)

WATERTOWN MA 02472

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Disc Medicine, Inc. [ IRON ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

3. Date of Earliest Transaction (Month/Day/Year)
09/09/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/09/2025		M		10,000	A	$1.01	171,828	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$1.01	09/09/2025		M			10,000	(1)	03/10/2030	Common Stock	10,000	$0	198,420	D

Explanation of Responses:

1. The shares underlying this option are fully vested and exercisable as of the date hereof.

	By: /s/ Rahul Khara, as Attorney-in-Fact	09/11/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Disc Medicine (IRON) CEO John D. Quisel report on Form 4?

He reported acquiring 10,000 shares of common stock at $1.01 and a reported option to buy 10,000 shares at $1.01, both dated 09/09/2025.

How many shares does John D. Quisel beneficially own after the transactions?

The filing shows 171,828 shares owned directly and 198,420 shares beneficially owned including derivative securities.

Are the reported stock options exercisable now and when do they expire?

Yes, the Form 4 states the optioned shares are fully vested and exercisable and the option expires on 03/10/2030.

What was the exercise price for the reported option and the purchase price for the shares?

Both the purchase price for the common shares and the option exercise price are listed as $1.01.

Who signed the Form 4 on behalf of the reporting person?

The form was signed by /s/ Rahul Khara, as Attorney-in-Fact on 09/11/2025.